Which has higher earnings & valuation, GRFS or VTRS?

Grifols has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 39.89 Viatris $14.56B 1.38 -$3.51B -$0.26 N/A

Is GRFS or VTRS more profitable?

Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Viatris -2.04% 19.04% 7.62%

Does the media favor GRFS or VTRS?

In the previous week, Viatris had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat Viatris' score of 0.47 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, GMAB or GRFS?

Genmab A/S has higher earnings, but lower revenue than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.90B 4.61 $963M $1.32 21.87 Grifols $8.51B 0.61 $454.82M $0.19 39.89

Is GMAB or GRFS more profitable?

Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Grifols 5.54% 6.21% 2.39%

Does the media prefer GMAB or GRFS?

In the previous week, Genmab A/S had 4 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Genmab A/S and 2 mentions for Grifols. Genmab A/S's average media sentiment score of 1.03 beat Grifols' score of 0.93 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, GRFS or ASND?

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 39.89 Ascendis Pharma A/S $814.57M 19.44 -$258M $8.67 29.28

Does the media refer more to GRFS or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Grifols. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Grifols' score of 0.93 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GRFS or BBIO?

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 39.89 BridgeBio Pharma $579.96M 28.37 -$724.93M -$3.74 N/A

Does the media favor GRFS or BBIO?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 2 mentions for Grifols. BridgeBio Pharma's average media sentiment score of 1.50 beat Grifols' score of 0.93 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor GRFS or ELAN?

In the previous week, Elanco Animal Health had 7 more articles in the media than Grifols. MarketBeat recorded 9 mentions for Elanco Animal Health and 2 mentions for Grifols. Elanco Animal Health's average media sentiment score of 1.27 beat Grifols' score of 0.93 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Grifols (GRFS) Competitors

$7.58 +0.04 (+0.53%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$7.60 +0.01 (+0.20%)

As of 07/24/2026 04:56 PM Eastern

Compare

GRFS vs. VTRS, GMAB, ASND, BBIO, and ELAN

Should you buy Grifols stock or one of its competitors? MarketBeat compares Grifols with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grifols include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Grifols compare to Viatris?

Grifols (NASDAQ:GRFS) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Grifols has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A

Grifols pays an annual dividend of $0.23 per share and has a dividend yield of 3.0%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Grifols pays out 121.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -184.6% of its earnings in the form of a dividend.

Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Viatris	-2.04%	19.04%	7.62%

79.9% of Viatris shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 31.93%. Viatris has a consensus target price of $17.50, indicating a potential upside of 1.51%. Given Grifols' higher possible upside, analysts plainly believe Grifols is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, Viatris had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Grifols. Grifols' average media sentiment score of 0.93 beat Viatris' score of 0.47 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Viatris beats Grifols on 11 of the 18 factors compared between the two stocks.

How does Grifols compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Genmab A/S has higher earnings, but lower revenue than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89

In the previous week, Genmab A/S had 4 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Genmab A/S and 2 mentions for Grifols. Genmab A/S's average media sentiment score of 1.03 beat Grifols' score of 0.93 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Grifols	5.54%	6.21%	2.39%

Genmab A/S currently has a consensus target price of $39.28, suggesting a potential upside of 36.05%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 31.93%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Genmab A/S beats Grifols on 15 of the 17 factors compared between the two stocks.

How does Grifols compare to Ascendis Pharma A/S?

Grifols (NASDAQ:GRFS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Grifols has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 31.93%. Ascendis Pharma A/S has a consensus target price of $296.72, suggesting a potential upside of 16.88%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Grifols. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Grifols' score of 0.93 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89
Ascendis Pharma A/S	$814.57M	19.44	-$258M	$8.67	29.28

Ascendis Pharma A/S has a net margin of 57.87% compared to Grifols' net margin of 5.54%. Grifols' return on equity of 6.21% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Summary

Ascendis Pharma A/S beats Grifols on 8 of the 15 factors compared between the two stocks.

How does Grifols compare to BridgeBio Pharma?

Grifols (NASDAQ:GRFS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89
BridgeBio Pharma	$579.96M	28.37	-$724.93M	-$3.74	N/A

99.8% of BridgeBio Pharma shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Grifols has a net margin of 5.54% compared to BridgeBio Pharma's net margin of -124.42%. Grifols' return on equity of 6.21% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Grifols presently has a consensus price target of $10.00, suggesting a potential upside of 31.93%. BridgeBio Pharma has a consensus price target of $95.21, suggesting a potential upside of 13.32%. Given Grifols' higher probable upside, equities analysts plainly believe Grifols is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 8 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 2 mentions for Grifols. BridgeBio Pharma's average media sentiment score of 1.50 beat Grifols' score of 0.93 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Grifols and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Grifols compare to Elanco Animal Health?

Grifols (NASDAQ:GRFS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Grifols has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	39.89
Elanco Animal Health	$4.89B	2.54	-$232M	-$0.50	N/A

Grifols has a net margin of 5.54% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Elanco Animal Health	-4.95%	7.42%	3.66%

Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

In the previous week, Elanco Animal Health had 7 more articles in the media than Grifols. MarketBeat recorded 9 mentions for Elanco Animal Health and 2 mentions for Grifols. Elanco Animal Health's average media sentiment score of 1.27 beat Grifols' score of 0.93 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols currently has a consensus target price of $10.00, suggesting a potential upside of 31.93%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 15.37%. Given Grifols' higher probable upside, equities research analysts plainly believe Grifols is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

97.5% of Elanco Animal Health shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Elanco Animal Health beats Grifols on 11 of the 17 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRFS vs. The Competition

Export

Metric	Grifols	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.13B	$3.08B	$6.88B	$12.25B
Dividend Yield	3.03%	2.07%	2.67%	9.79%
P/E Ratio	39.89	20.29	27.00	23.71
Price / Sales	0.61	345.71	492.66	73.79
Price / Cash	5.32	27.62	50.54	59.64
Price / Book	0.60	4.13	10.28	6.07
Net Income	$454.82M	$65.94M	$3.60B	$331.84M
7 Day Performance	4.26%	-4.18%	-1.25%	-1.53%
1 Month Performance	2.85%	-3.76%	-0.35%	-2.46%
1 Year Performance	-24.95%	9.93%	18.41%	13.66%

Grifols Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRFS Grifols	4.4943 of 5 stars	$7.58 +0.5%	$10.00 +31.9%	-23.7%	$5.13B	$8.51B	39.89	25,247	Upcoming Earnings High Trading Volume
VTRS Viatris	2.5464 of 5 stars	$16.39 +0.7%	$17.50 +6.8%	+84.4%	$18.95B	$14.30B	N/A	30,000	Analyst Upgrade
GMAB Genmab A/S	4.7923 of 5 stars	$28.80 -0.7%	$38.21 +32.7%	+22.2%	$18.08B	$3.72B	21.82	3,029	Analyst Upgrade High Trading Volume
ASND Ascendis Pharma A/S	4.7302 of 5 stars	$265.22 -1.9%	$295.67 +11.5%	+50.8%	$16.87B	$814.57M	30.59	1,189	News Coverage Positive News Analyst Forecast
BBIO BridgeBio Pharma	2.9786 of 5 stars	$83.08 -3.3%	$94.63 +13.9%	+84.0%	$16.82B	$502.08M	N/A	400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRFS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Competitors

GRFS vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Grifols compare to Viatris?

Summary

How does Grifols compare to Genmab A/S?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Summary

How does Grifols compare to BridgeBio Pharma?

Summary

How does Grifols compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grifols (GRFS) Competitors

GRFS vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Grifols compare to Viatris?

Which has higher earnings & valuation, GRFS or VTRS?

Is GRFS or VTRS a better dividend stock?

Is GRFS or VTRS more profitable?

Do insiders & institutionals have more ownership in GRFS or VTRS?

Do analysts prefer GRFS or VTRS?

Which has more volatility & risk, GRFS or VTRS?

Does the media favor GRFS or VTRS?

Summary

How does Grifols compare to Genmab A/S?

Which has stronger earnings & valuation, GMAB or GRFS?

Does the media prefer GMAB or GRFS?

Do institutionals and insiders have more ownership in GMAB or GRFS?

Which has more risk & volatility, GMAB or GRFS?

Is GMAB or GRFS more profitable?

Do analysts rate GMAB or GRFS?

Summary

How does Grifols compare to Ascendis Pharma A/S?

Which has more risk & volatility, GRFS or ASND?

Do analysts recommend GRFS or ASND?

Does the media refer more to GRFS or ASND?

Which has higher earnings and valuation, GRFS or ASND?

Is GRFS or ASND more profitable?

Summary

How does Grifols compare to BridgeBio Pharma?

Which has stronger valuation and earnings, GRFS or BBIO?

Do institutionals and insiders have more ownership in GRFS or BBIO?

Is GRFS or BBIO more profitable?

Which has more volatility & risk, GRFS or BBIO?

Do analysts rate GRFS or BBIO?

Does the media favor GRFS or BBIO?

Summary

How does Grifols compare to Elanco Animal Health?

Which has higher earnings and valuation, GRFS or ELAN?

Is GRFS or ELAN more profitable?

Which has more risk and volatility, GRFS or ELAN?

Does the media favor GRFS or ELAN?

Do analysts prefer GRFS or ELAN?

Do institutionals and insiders believe in GRFS or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools